본문 바로가기 주메뉴 바로가기
home
ABOUT US

2023

  • IP Applications for New CRBN E3 binder & PROTAC

    - JAPAN/CHINA

  • Relocation of HQ and R&D center in Pangyo
  • 2nd KDDF Award for Preclinical development of cMET targeting degrader
  • 3rd KDDF Award for Candidate development of BRD4-NUT targeting degrader
  • Bridge Funding completed

2022

  • IP Registration for ELCBIL

    - Korea

  • IP Applications for new small molecules that inhibit c-MET

    - KOREA / PCT

  • IP Application for PROTACs degrading c-MET/BET

    - KOREA / PCT

  • IP Application for New CRBN E3 binder & PROTAC

    - USA / EU

  • IP Application for MILPROTAC

    - KOREA / PCT

  • Joint Development of PROTAC with

    - 'L' Bio Company

    - 'I' Company

2021

  • IP Application for New CRBN E3 binder & PROTAC

    - Korea / PCT

    - IP of small molecule warhead

  • Joint Development of PROTAC with

    - 'S' Bio Company

  • Awarded the Start-up Leap Forward Package by the Ministry of SMEs and Startups (MSS)

2020

  • New chemical R&D center in Gwanggyo
  • InnoCure Therapeutics wins the Digital Innovation Grand Award
  • Series A funding completed
  • Certificated Venture Company (KIBO)

2019

  • New R&D center with expanded facilities in Pangyo
  • Pre-A funding completed
  • New R&D center in Pangyo
  • Investment from TIPS program/VC

2018

  • Seed from Korea Credit Guarantee Fund (KCGF)
  • InnoCure Therapeutics founded